Vendor Intelligence Report: Cactus Peptides

Published 3 Jul 2026. 20-page investigative report on who is behind Cactus Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Cactus Peptides is a narrow positive, not a catalog-wide green light. Across 4 Finnrick lab tests the overall pass rate is 100%: 4 pass and 0 fail. The clean record covers only Retatrutide and Tirzepatide, both rating just above 81% under Finnrick’s public methodology, so the best buyer read is product-specific confidence for those two compounds rather than trust in every vial on the storefront.

The investigation’s tension is that the lab signal is cleaner than the public accountability file. The domain record is recent and privacy-redacted, Arizona registry searches did not surface a Cactus Peptides entity under the brand name, and the listed Chandler contact point resolves to a PostNet private mailbox rather than a verifiable operating facility. No named owner, officer, founder, or manufacturer appears in the reviewed materials.

The storefront is active and broader than the tested set. Field captures show newer products such as GLP-3 and the Wolverine Stack outside Finnrick’s Cactus-specific testing record, while Certificate Transparency logs expose an sst.cactuspeptides.com subdomain consistent with a backend or serverless layer but not a public page. That infrastructure suggests an operating buildout; it does not answer ownership or batch-source questions.

Public-market noise is unusually low. Covered X, coupon-site, and web-indexed Reddit promotion sweeps found no affiliate-code network, no visible coupon farm, and no relevant Reddit footprint; Trustpilot sentiment exists but is small. Directionally, Cactus Peptides is most defensible for Retatrutide or Tirzepatide buyers who can tolerate operator opacity, and weaker for buyers seeking untested catalog items or a named legal counterparty.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with per-product pass/fail records and methodology-divergence charts for both tested products
  • ICANN RDAP/WHOIS and Arizona registry research trail for the Cactus Peptides identity
  • Addressability check showing the Chandler PMB and the absence of a verified physical facility
  • Certificate Transparency exhibit for sst.cactuspeptides.com and backend-infrastructure interpretation
  • Catalog-gap analysis covering GLP-3, BPC-157, TB-500, and Wolverine Stack versus tested products
  • Affiliate, coupon-site, Reddit, Trustpilot, FDA, policy-text, and sister-brand search results with coverage limits

Risk assessment

  • Ownership and recourse opacity risk — high: No owners/legal entity identified, redacted RDAP, and Chandler PostNet PMB leave buyers without a verifiable counterparty.
  • Untested-product coverage risk — medium: Finnrick data covers Retatrutide and Tirzepatide only; GLP-3, BPC-157, TB-500, and Wolverine Stack have no Finnrick product-specific validation.